PARP Inhibitors: Staying on Target?

Craig L Doig, Gareth G Lavery

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
195 Downloads (Pure)


Successful phase III trials with poly-ADP-ribose (PARP) inhibitors will have implications for stratified cancer therapy. In this issue of Cell Chemical Biology, Knezevic et al. (2016) demonstrate that the existing collection of PARP inhibitors each display distinctive protein interaction profiles, reaching beyond their intended therapeutic target, with implications for metabolic and other disease.

Original languageEnglish
Pages (from-to)1442-1443
Number of pages2
JournalCell Chemical Biology
Issue number12
Publication statusPublished - 22 Dec 2016


Dive into the research topics of 'PARP Inhibitors: Staying on Target?'. Together they form a unique fingerprint.

Cite this